KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis

Laurence Beck, Andrew S. Bomback, Michael J Choi, Larry B. Holzman, Carol Langford, Laura H. Mariani, Michael J. Somers, Howard Trachtman, Meryl Waldman

Research output: Contribution to journalArticle

Abstract

Glomerulonephritis (GN) is an important cause of morbidity and mortality in patients of all ages throughout the world. Because these disorders are relatively rare, it is difficult to perform randomized clinical trials to define optimal treatment for many of the specific glomerulopathies. In the absence of high-grade evidence to guide the care of glomerular diseases, in June 2012, KDIGO (Kidney Disease: Improving Global Outcomes) published an international clinical guideline for GN. The Work Group report represents an important review of the literature in this area and offers valid and useful guidelines for the most common situations that arise in the management of patients with glomerular disease. This commentary, developed by a panel of clinical experts convened by the National Kidney Foundation, attempts to put the GN guideline into the context of the US health care system. Overall, we support the vast majority of the recommendations and highlight select areas in which epidemiological factors and medical practice patterns in this country justify modifications and adjustments in order to achieve favorable outcomes. There remain large gaps in our knowledge of the best approaches to treat glomerular disease and we strongly endorse an expanded clinical research effort to improve the health and long-term outcomes of children and adults with GN.

Original languageEnglish (US)
Pages (from-to)403-441
Number of pages39
JournalAmerican Journal of Kidney Diseases
Volume62
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Kidney Diseases
Glomerulonephritis
Practice Guidelines
Guidelines
Randomized Controlled Trials
Morbidity
Delivery of Health Care
Kidney
Mortality
Health
Research
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Beck, L., Bomback, A. S., Choi, M. J., Holzman, L. B., Langford, C., Mariani, L. H., ... Waldman, M. (2013). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. American Journal of Kidney Diseases, 62(3), 403-441. https://doi.org/10.1053/j.ajkd.2013.06.002

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. / Beck, Laurence; Bomback, Andrew S.; Choi, Michael J; Holzman, Larry B.; Langford, Carol; Mariani, Laura H.; Somers, Michael J.; Trachtman, Howard; Waldman, Meryl.

In: American Journal of Kidney Diseases, Vol. 62, No. 3, 09.2013, p. 403-441.

Research output: Contribution to journalArticle

Beck, L, Bomback, AS, Choi, MJ, Holzman, LB, Langford, C, Mariani, LH, Somers, MJ, Trachtman, H & Waldman, M 2013, 'KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis', American Journal of Kidney Diseases, vol. 62, no. 3, pp. 403-441. https://doi.org/10.1053/j.ajkd.2013.06.002
Beck, Laurence ; Bomback, Andrew S. ; Choi, Michael J ; Holzman, Larry B. ; Langford, Carol ; Mariani, Laura H. ; Somers, Michael J. ; Trachtman, Howard ; Waldman, Meryl. / KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. In: American Journal of Kidney Diseases. 2013 ; Vol. 62, No. 3. pp. 403-441.
@article{5b4f67a3bc7f41ab9ef0f91798d67357,
title = "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis",
abstract = "Glomerulonephritis (GN) is an important cause of morbidity and mortality in patients of all ages throughout the world. Because these disorders are relatively rare, it is difficult to perform randomized clinical trials to define optimal treatment for many of the specific glomerulopathies. In the absence of high-grade evidence to guide the care of glomerular diseases, in June 2012, KDIGO (Kidney Disease: Improving Global Outcomes) published an international clinical guideline for GN. The Work Group report represents an important review of the literature in this area and offers valid and useful guidelines for the most common situations that arise in the management of patients with glomerular disease. This commentary, developed by a panel of clinical experts convened by the National Kidney Foundation, attempts to put the GN guideline into the context of the US health care system. Overall, we support the vast majority of the recommendations and highlight select areas in which epidemiological factors and medical practice patterns in this country justify modifications and adjustments in order to achieve favorable outcomes. There remain large gaps in our knowledge of the best approaches to treat glomerular disease and we strongly endorse an expanded clinical research effort to improve the health and long-term outcomes of children and adults with GN.",
author = "Laurence Beck and Bomback, {Andrew S.} and Choi, {Michael J} and Holzman, {Larry B.} and Carol Langford and Mariani, {Laura H.} and Somers, {Michael J.} and Howard Trachtman and Meryl Waldman",
year = "2013",
month = "9",
doi = "10.1053/j.ajkd.2013.06.002",
language = "English (US)",
volume = "62",
pages = "403--441",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis

AU - Beck, Laurence

AU - Bomback, Andrew S.

AU - Choi, Michael J

AU - Holzman, Larry B.

AU - Langford, Carol

AU - Mariani, Laura H.

AU - Somers, Michael J.

AU - Trachtman, Howard

AU - Waldman, Meryl

PY - 2013/9

Y1 - 2013/9

N2 - Glomerulonephritis (GN) is an important cause of morbidity and mortality in patients of all ages throughout the world. Because these disorders are relatively rare, it is difficult to perform randomized clinical trials to define optimal treatment for many of the specific glomerulopathies. In the absence of high-grade evidence to guide the care of glomerular diseases, in June 2012, KDIGO (Kidney Disease: Improving Global Outcomes) published an international clinical guideline for GN. The Work Group report represents an important review of the literature in this area and offers valid and useful guidelines for the most common situations that arise in the management of patients with glomerular disease. This commentary, developed by a panel of clinical experts convened by the National Kidney Foundation, attempts to put the GN guideline into the context of the US health care system. Overall, we support the vast majority of the recommendations and highlight select areas in which epidemiological factors and medical practice patterns in this country justify modifications and adjustments in order to achieve favorable outcomes. There remain large gaps in our knowledge of the best approaches to treat glomerular disease and we strongly endorse an expanded clinical research effort to improve the health and long-term outcomes of children and adults with GN.

AB - Glomerulonephritis (GN) is an important cause of morbidity and mortality in patients of all ages throughout the world. Because these disorders are relatively rare, it is difficult to perform randomized clinical trials to define optimal treatment for many of the specific glomerulopathies. In the absence of high-grade evidence to guide the care of glomerular diseases, in June 2012, KDIGO (Kidney Disease: Improving Global Outcomes) published an international clinical guideline for GN. The Work Group report represents an important review of the literature in this area and offers valid and useful guidelines for the most common situations that arise in the management of patients with glomerular disease. This commentary, developed by a panel of clinical experts convened by the National Kidney Foundation, attempts to put the GN guideline into the context of the US health care system. Overall, we support the vast majority of the recommendations and highlight select areas in which epidemiological factors and medical practice patterns in this country justify modifications and adjustments in order to achieve favorable outcomes. There remain large gaps in our knowledge of the best approaches to treat glomerular disease and we strongly endorse an expanded clinical research effort to improve the health and long-term outcomes of children and adults with GN.

UR - http://www.scopus.com/inward/record.url?scp=84883237470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883237470&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2013.06.002

DO - 10.1053/j.ajkd.2013.06.002

M3 - Article

VL - 62

SP - 403

EP - 441

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 3

ER -